Xenograft models to study stem and chemoresistant cells, and to assess the in vivo efficacy of new anti-cancer agents

We have recently contributed to establish a robust xenotransplantation model (NSG, NRG) to study the leukemic engraftment as well as the stem cell biology in acute leukemias. Others and we also suggest that these highly immunocompromised mice represent a powerful in vivo model to screen new therapeutic strategies (kinase inhibitors, epigentic agents, metabolic agents) and to mimic the chemoresistance and minimal residual disease observed in leukemic patients after chemotherapy. The study of the in vivo chemoresistance is crucial to improve therapeutic outcome of leukemia patients.

Interest / Relevance: Our expertise is relevant to study and develop new targets and agents in hematology and leukemia.

Our skills with these xenograft models could also find othher applications in immunology (HIV), diabetes and other cancers.
Keywords: preclinical model , stem cell , cancer , hematology , metabolism
Scientist's name: Jean-Emmanuel SARRY
Stephane Manenti, Christian Recher



Business Developper
Jean-Emmanuel SARRY
Inserm Transfert
Research Tools
Accessible for: Fee-for-service research, Collaboration, Training / Know-How License
Equipment available: Space into the xenograft mice facilities.
Samples/Models available: NSG (NOD/LtSz-scid/IL2Rãchain null), NRG (NOD/RAG2/IL2Rychain null) mice
Primary leukemic cells from patients with acute myeloid and lymphoid leukemia;
Rare disease:
Last update: 13/12/2021

You might also be interested in